

ANSWERING REVIEWERS



June 6, 2016

Dear Editor,

Please find enclosed the edited manuscript in Word format (26137-review.doc).

Title: Update on the treatment of type 2 diabetes mellitus

Author: Juan José Marín-Peñalver, Iciar Martín-Timón, Cristina Sevillano-Collantes, Francisco Javier del Cañizo-Gómez

Name of Journal: *World Journal of Diabetes*

ESPS Manuscript NO: 26137

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(02623960):

- The recommendations of the AACE 2016 on sleep in lifestyle modification were added (page 5, lines 10-16, References: 11,12).
- The font size of the algorithm on CKD in diabetes was increased.
- Many sentences starting as "is used as" were changed by others starting as "is utilized as".
- Spelling mistakes were corrected
- References have been put in all tables and figures

(00051227):

- As invited manuscript, there was no limitation in the number of words, tables and figures.
- Several errors in the text and some statements not precisely written, were corrected.
- All abbreviations were ordered, and others, as Hb A1c, were corrected.
- Figures 1 and 2 were omitted.

(01198134):

None

(00506298):

- As invited manuscript, there was no limitation in the number of words, tables and figures.
- The paragraphs talking about type 1 diabetes was deleted
- Information about diabetes ketoacidosis with the use of sodium glucose co-transporter-2 inhibitors was added (page 38, lines 22-26; references: 169,170).
- Although the parts on special situations, such as kidney diseases and older people, might be matter of other manuscripts, we believe that both add value to the manuscript.

(00674619):

- Spelling mistakes were corrected

(00506250):

- Information about colesevelam, bromocriptine and amylin was added (page 51, lines 14-30, page 52, and page 53, lines: 1-18, references: 221-232).
- Information about GPR 119 agonists, oral GLP-1 receptor agonists, oral insulin, and SGLT-1/2 dual inhibitor was added (page 73, lines 17-29, pages 74 and 75, and page 76, lines 1-8; references: 362-374).

(02446593)

- A review of the English language to correct grammatical errors and unclear sentences, was performed..

15 duplicate references were deleted.

Thank you again for publishing our manuscript in the *World Journal of Diabetes*.

Sincerely yours,



Peter Laszlo LAKATOS, MD, PhD
1st Dept. of Medicine
Semmelweis University
Budapest, Koranyi 2A
H-1083-Hungary
Fax: +36-1-313-0250
E-mail: kislakpet@bell.sote.hu